Provided by Tiger Trade Technology Pte. Ltd.

CUTIA-B

0.870
-0.005-0.57%
Volume:439.00K
Turnover:390.79K
Market Cap:324.51M
PE:-0.84
High:0.910
Open:0.880
Low:0.870
Close:0.875
52wk High:9.190
52wk Low:0.740
Shares:373.00M
HK Float Shares:373.00M
Volume Ratio:0.43
T/O Rate:0.12%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.030
ROE:-38.30%
ROA:-14.05%
PB:0.39
PE(LYR):-0.84
PS:0.83

Loading ...

CUTIA-B Reports Stable Share Base in September; Minor Forfeitures in Pre-IPO Incentive Plans, Public Float Intact

Bulletin Express
·
Oct 02

Cutia Therapeutics - B: Lele Zhang Disposes of Shares, Long Position Falls to 7.09%

HK Disclosure
·
Oct 02

CUTIA-B: Lele Zhang Disposes of Shares, Long Position Falls to 6.74%

HK Disclosure
·
Oct 02

Have Insiders Sold Cutia Therapeutics Shares Recently?

Simply Wall St.
·
Oct 01

Cutia Therapeutics to Launch Up to 30 Million Yuan Share Buyback

MT Newswires Live
·
Sep 30

Cutia Therapeutics Announces RMB30.00 Million Share Repurchase Programme for 4Q26

Bulletin Express
·
Sep 30

CUTIA-B (02487) Plans to Execute a Share Buyback Program

Stock News
·
Sep 30

Cutia Therapeutics - to Implement Share Repurchase Program from Oct 2 to Dec 31, 2026

THOMSON REUTERS
·
Sep 30

Cutia Therapeutics - Maximum Funds for Repurchase Set at RMB30 Mln, up to 36.3 Mln Shares

THOMSON REUTERS
·
Sep 30

CUTIA-B (02487): Lei Lei Appointed as Executive Director

Stock News
·
Sep 30

Cutia Therapeutics - Mr. Huang Yuqing Resigns as Executive Director and CFO Effective 30 September 2026

THOMSON REUTERS
·
Sep 30

CUTIA-B: Lele Zhang Disposes of Shares, Long Position Falls to 7.12%

HK Disclosure
·
Sep 25

CUTIA-B: Lele Zhang Disposes of Shares, Long Position Falls to 7.32%

HK Disclosure
·
Sep 25

Hong Kong Market Movers: CUTIA-B (02487) Climbs Over 3% Following Macau Drug Approval

Stock News
·
Sep 24

Cutia Therapeutics Gets Macao Approval for Topical Finasteride Spray

MT Newswires Live
·
Sep 21

CUTIA-B Receives Macau Regulatory Approval for Topical Finasteride Spray Product

Stock News
·
Sep 21

Cutia Therapeutics: CU-40102 Topical Finasteride Spray Gains Macao Marketing Approval, Complementing China and Hong Kong Clearances

Bulletin Express
·
Sep 21

Cutia Therapeutics - Cu-40102 Obtains Marketing Approval from Macao Pharmaceutical Administration Bureau

THOMSON REUTERS
·
Sep 21

CUTIA-B Records Stable Share Base in August 2026; Confirms Public Float Compliance

Bulletin Express
·
Sep 04

Cutia Therapeutics' Marketing Application for Botox Product Accepted in China

MT Newswires Live
·
Sep 03